Fiala

Peptide library › Metabolic & weight

Amycretin

In clinical trialsMetabolic & weight

Experimental single molecule that acts on both GLP-1 and amylin receptors, tested as a weekly injection and a daily tablet for weight loss.

What people use it for

What Amycretin does in the body

One molecule that activates two appetite systems: GLP-1 receptors, like semaglutide, and amylin receptors, like cagrilintide. Both reduce hunger and slow stomach emptying, and combining them may give more weight loss than either alone.

Strength of evidence

Moderate: early-phase (Phase 1/2) trials showed large weight loss in people with overweight or obesity. Large Phase 3 trials are still needed.

Look up the evidence

Live searches of official databases. New to the terms? See the glossary.

Reported side effects & risks

Who should avoid it or take extra care

Not a complete list. Check with a doctor or pharmacist about your own health and medicines.

Regulatory status

Investigational. Not approved by the FDA or any regulator.

How it's taken

Route: Injection under the skin once weekly, or a daily tablet (in trials)

How long it lasts (half-life): Long-acting injection designed for weekly dosing; full data not yet published

Keep track of Amycretin privately

Fiala is a free app for logging doses, tracking vials and setting reminders. No account, and everything you log stays on your phone.

Open Amycretin in Fiala How to install
Not medical advice. This page is general education. Talk to a qualified clinician before starting, stopping or changing any treatment.

More in Metabolic & weight